Journal article icon

Journal article

Gene editing of CD3 epsilon gene to redirect regulatory T cells for adoptive T cell transfer

Abstract:
Adoptive transfer of antigen-specific regulatory T cells (Tregs) is a promising strategy to combat immunopathologies in transplantation and autoimmune diseases. However, their low frequency in peripheral blood poses challenges for both manufacturing and clinical application. Chimeric antigen receptors (CARs) have been used to redirect the specificity of Tregs, employing retroviral vectors. However, retroviral gene transfer is costly, time consuming, and raises safety issues. Here, we explored non-viral CRISPR-Cas12a gene editing to redirect Tregs, using HLA-A2-specific constructs for proof-of-concept studies in transplantation models. Knock-in of an antigen-binding domain into the N terminus of CD3 epsilon (CD3ε) gene generates Tregs expressing a chimeric CD3ε-T cell receptor fusion construct (TRuC) protein which integrates into the endogenous TCR/CD3 complex. These CD3ε-TRuC Tregs exhibit potent antigen-dependent activation while maintaining responsiveness to TCR/CD3 stimulation. This enables preferential enrichment of TRuC-redirected Tregs over CD3ε KO Tregs via repetitive CD3/CD28-stimulation in a GMP-compatible expansion system. CD3ε-TRuC Tregs retained their phenotypic, epigenetic, and functional identity. In a humanized mouse model, HLA-A2-specific CD3ε-TRuC Tregs demonstrate superior protection of allogeneic HLA-A2<sup>+</sup> skin grafts from rejection compared to polyclonal Tregs. This approach provides a pathway for developing clinical-grade CD3ε-TRuC-based Treg cell products for transplantation immunotherapy and other immunopathologies.
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Files:
Publisher copy:
10.1016/j.ymthe.2025.01.045

Authors


More from this funder
Funder identifier:
https://ror.org/029chgv08
Grant:
105605/Z/14/Z
204826/Z/16/Z
More from this funder
Funder identifier:
https://ror.org/00k4n6c32
Grant:
825392
More from this funder
Funder identifier:
https://ror.org/03x94j517
Grant:
MR/N027930/1
More from this funder
Funder identifier:
https://ror.org/0472cxd90


Publisher:
Cell Press
Journal:
Molecular Therapy More from this journal
Volume:
33
Issue:
3
Pages:
997-1013
Place of publication:
United States
Publication date:
2025-02-03
Acceptance date:
2025-01-30
DOI:
EISSN:
1525-0024
ISSN:
1525-0016
Pmid:
39905729


Language:
English
Keywords:
Pubs id:
2084598
Local pid:
pubs:2084598
Deposit date:
2025-02-25
ARK identifier:

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP